NOT medical advice. Always consult a healthcare professional. NOT affiliated with or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

Emergency?Call 999

Need NHS advice?Call 111

Loading...

Dicycloverine 10mg/5ml oral solution

Prescription only

Requires a prescription from a doctor or prescriber

Oral solution

10mg/5ml

Oral

Active ingredients:

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC A03AA07

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Dicycloverine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Dicycloverine

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Dicycloverine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

14 branded products available

14 products

14 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Dicycloverine on the MHRA register

Dicycloverine 10mg/5ml oral solution

Alliance Healthcare (Distribution) Ltd

Dicycloverine 10mg/5ml oral solution

A A H Pharmaceuticals Ltd

Dicycloverine 10mg/5ml oral solution

Phoenix Healthcare Distribution Ltd

Dicycloverine 10mg/5ml oral solution

Dicycloverine 10mg/5ml oral solution

Dicycloverine 10mg/5ml oral solution

Medihealth (Northern) Ltd

Merbentyl 10mg/5ml syrup

Discontinued

Dicycloverine 10mg/5ml oral solution

Zentiva Pharma UK Ltd

Discontinued

Dicycloverine 10mg/5ml oral solution

Waymade Healthcare Plc

Discontinued

Dicycloverine 10mg/5ml oral solution

Sigma Pharmaceuticals Plc

Discontinued

Dicycloverine 10mg/5ml oral solution

Advanz Pharma

Discontinued

Dicycloverine 10mg/5ml oral solution

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Price & daily dose

£174.11indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

80 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similar

Dicycloverine 10mg/5ml oral solution sugar free

Same therapeutic group

Mebeverine 150mg/5ml oral suspension

Oral suspension

Same therapeutic group

Mebeverine 135mg oral powder sachets

Same therapeutic group

Mebeverine 50mg/5ml oral suspension

Oral suspension

Same therapeutic group

Mebeverine 100mg tablets

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

Pharmacy2U

Search products

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42353111000001102

dm+d ID

42353111000001102

VTM (Virtual Therapeutic Moiety)

775568004

VMP (Virtual Medicinal Product)

42353111000001102

BNF code (NHS dm+d)

01020000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

A03AA07

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing all 25 studies.

1990–2026

Sort

Dicycloverine/Paracetamol abuse

Reactions Weekly, 2025

Dicycloverine/Loperamide/Plantago-ovata

Reactions Weekly, 2025

Dicycloverine/paracetamol

Reactions Weekly, 2025

Dicycloverine/diphenhydramine/rivastigmine

Reactions Weekly, 2023

Dicycloverine/hydrocodone/paracetamol

Reactions Weekly, 2023

Dicycloverine/hyoscyamine/sucralfate

Reactions Weekly, 2023

Alprazolam/Dicycloverine/paracetamol/tramadol

Reactions Weekly, 2024

Analytical Method Validation for Related Substances of Dicycloverine Tablets 10 mg, 20 mg by HPLC

R. Linga Reddy Mallampati, Prof. D. Ramsachandran

IJPAR JOURNAL, 2026

DEVELOPMENT AND EVALUATION OF GASTRO-RETENTIVE FLOATING BEADS OF DICYCLOVERINE HYDROCHLORIDE

Monika Setia, Kapil Kumar, Deepak Teotia

Journal of Drug Delivery and Therapeutics, 2018

Cited by 2

Meyler's Side Effects of Drugs, 2016

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

1.8 hours

Mechanism

Dicyclomine achieves its action partially through direct antimuscarinic activity…

Food interactions

2 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

1-1.5h

The bioavailability of dicyclomine has not been determined,[A182534] though it is likely well absorbed as the primary route of elimination is in the urine.
[A182525][L7967]…

Half-life

1.8 hours

The mean plasma elimination half life is approximately 1.8 hours.
[A182525][L7967]

Protein binding

Data regarding plasma protein binding of dicyclomine is not readily available.
[L7967]

Volume of distribution

20mg

The volume of distribution for a 20mg oral dose is 3.65L/kg.
[L7967]

Metabolism

The metabolism of dicyclomine has not been well researched.
[A182525]

Elimination

79.5%

Dicyclomine is 79.5% eliminated in the urine and 8.4% in the feces.
[A182525][L7967]

Clearance

Data regarding the clearance of dicyclomine is not readily available.
[L7967]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556][A182555][A234659][L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982]

Dicyclomine was granted FDA approval on 11 May 1950.[L7967]

Properties:

solid

Avg. mass: 309.49 Da

View FDA drug label

DrugBank indication

Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.
[L7967]

Also known as(7)

2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate

Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester

Dicicloverina

Dicyclomine

Dicycloverin

Dicycloverine

Dicycloverinum

Molecular properties(18)

Drug interactions(1148)

Known interactions with other medications. Always consult a healthcare professional.

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Aclidinium.

Check this interaction

Moderate

Mianserin may increase the anticholinergic activities of Dicyclomine.

Check this interaction

Unknown severity

The risk or severity of urinary retention can be increased when Dicyclomine is combined with Mirabegron.

Check this interaction

Unknown severity

The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dicyclomine.

Check this interaction

Secretin porcine

Moderate

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Dicyclomine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tiotropium.

Check this interaction

Unknown severity

The risk or severity of hyperthermia and oligohydrosis can be increased when Dicyclomine is combined with Topiramate.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Umeclidinium.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glycopyrronium.

Check this interaction

Botulinum toxin type A

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type A.

Check this interaction

Moderate

Dicyclomine may increase the gastrointestinal motility reducing activities of Glucagon.

Check this interaction

Moderate

Dicyclomine may increase the anticholinergic activities of Sulpiride.

Check this interaction

Botulinum toxin type B

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type B.

Check this interaction

Unknown severity

The risk or severity of constipation can be increased when Dicyclomine is combined with Eluxadoline.

Check this interaction

Unknown severity

The risk or severity of constipation can be increased when Dicyclomine is combined with Ramosetron.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Naltrexone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.

Check this interaction

Dextropropoxyphene

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.

Check this interaction

Levacetylmethadol

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levacetylmethadol.

Check this interaction

Methadyl acetate

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl acetate.

Check this interaction

Dihydroetorphine

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diamorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Desomorphine.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.

Check this interaction

Alphacetylmethadol

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphacetylmethadol.

Check this interaction

Dihydromorphine

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.

Check this interaction

Unknown severity

The risk or severity of urinary retention and constipation can be increased when Dicyclomine is combined with Tapentadol.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Dicyclomine is combined with DPDPE.

Check this interaction

Showing 50 of 1148 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Alcohol may increase drowsiness caused by dicyclomine.

Advice

Drink plenty of fluids. Dicyclomine may reduce sweating, increasing the risk of overheating in warm weather or during exercise.

Toxicity & overdose

Patients experiencing an overdose may present with headache, nausea, vomiting, blurred vision, dilated pupils, dizziness, dry mouth, difficulty swallowing, CNS stimulation, as well as hot, dry skin.
[L7967]
Treat patients with gastric lavage, emetics, activated charcoal, sedatives for excitement, and a cholinergic agent if indicated.
[L7967]

The oral LD₅₀ in mice is 625mg/kg.
[L7967]

How it works

Mechanism of action

Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.[A6556][A182555][A234659][L7967] Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.[A182555]

Pharmacodynamics

Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.[L7967] It's duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.[L7967] Dicyclomine should not be administered intravenously.[L7967]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The bioavailability of dicyclomine has not been determined,[A182534] though it is likely well absorbed as the primary route of elimination is in the urine.
[A182525][L7967]
Dicyclomine has a T_max of 1-1.5h.
[L7967]

Half-life

The mean plasma elimination half life is approximately 1.8 hours.
[A182525][L7967]

Protein binding

Data regarding plasma protein binding of dicyclomine is not readily available.
[L7967]

Volume of distribution

The volume of distribution for a 20mg oral dose is 3.65L/kg.
[L7967]

Metabolism

The metabolism of dicyclomine has not been well researched.
[A182525]

Route of elimination

Dicyclomine is 79.5% eliminated in the urine and 8.4% in the feces.
[A182525][L7967]

Clearance

Data regarding the clearance of dicyclomine is not readily available.
[L7967]

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Muscarinic acetylcholine receptor M1

CHRM1

antagonist

Specific functionG protein-coupled acetylcholine receptor activity

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

Muscarinic acetylcholine receptor M3

CHRM3

antagonist

Specific functionacetylcholine binding

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

Muscarinic acetylcholine receptor M2

CHRM2

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol

Scientific references(5)

Danhof I., Schreiber E., Wiggans D., Leyland H.

Metabolic dynamics of dicyclomine hydrochloride in man as influenced by various dose schedules and formulations.

Toxicology and Applied Pharmacology

196813(1):16-23. doi: 10.1016/0041-008x(68)90128-2

DOI: 10.1016/0041-008x(68)90128-2

Walker B.J., Lang J.F., Okerholm R.A.

Quantitative analysis of dicyclomine in human plasma by capillary gas chromatography and nitrogen-selective detection.

Journal Chromatogr

1987 Apr 24416(1):150-3. doi: 10.1016/0378-4347(87)80496-6

PMID: 3597632 DOI: 10.1016/0378-4347(87)80496-6

Pavia J., Munoz M., Jimenez E., Martos F., Gonzalez-Correa J.A., De la Cruz J.P., Garcia V., Sanchez de la Cuesta F.

Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes.

European Journal of Pharmacology

1997320(2-3):209-214. doi: 10.1016/s0014-2999(96)00889-8

PMID: 9059856 DOI: 10.1016/s0014-2999(96)00889-8

MCGRATH W.R., LEWIS R.E., KUHN W.L.

THE DUAL MODE OF THE ANTISPASMODIC EFFECT OF DICYCLOMINE HYDROCHLORIDE.

The Journal of Pharmacology and Experimental Therapeutics

1964146(3):354-358. doi: 10.1016/s0022-3565(25)26933-6

PMID: 14254329 DOI: 10.1016/s0022-3565(25)26933-6

Doods H.N., Mathy M.J., Davidesko D., van Charldorp K.J., de Jonge A., van Zwieten P.A.

Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors..

The Journal of Pharmacology and Experimental Therapeutics

1987242(1):257-262. doi: 10.1016/s0022-3565(25)39062-2

PMID: 3612532 DOI: 10.1016/s0022-3565(25)39062-2

ATC classification(1 code)

ATC A03AA07

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Dicyclomine hydrochloride(DBSALT000698)

Experimental properties(1)

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Dicyclomine

Matched from: Dicycloverine

CAS number

77-19-0

UNII (FDA)

4KV4X8IF6V

InChI Key (molecular fingerprint)

CURUTKGFNZGFSE-UHFFFAOYSA-N

Synonym match

95% confidence

Additional database identifiers

Drugs Product Database (DPD)

6425

ChEBI

4514

PubChem Compound

3042

PubChem Substance

46505371

KEGG Compound

C06951

ChemSpider

2934

BindingDB

50010101

PharmGKB

PA164744928

Therapeutic Targets Database

DAP001118

IUPHAR

355

Guide to Pharmacology

355

Wikipedia

Dicycloverine

ChEMBL

CHEMBL1123

ZINC

ZINC000001530613

RxCUI

3361

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

13

Guide to Pharmacology

13

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

15

Guide to Pharmacology

15

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

14

Guide to Pharmacology

14

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(8 Mar 2026)

Structured knowledge from the free knowledge base

Wikipedia article

chemical compound

Read on Wikipedia

WHO INN:dicycloverine

International Nonproprietary Name

Research database identifiers

MeSH

D004025

ChEBI

CHEBI:4514

ATC classifications (Wikidata)

Linked open data from Wikidata (Q2662662), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.

Source: Q2662662CC0 1.0

Updated about 3 hours ago(5 Jul 2026)

Back to medicines